| Quest – Discovery Stage Research Projects | University of California, Los Angeles | Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$1,177,739 |
| Quest – Discovery Stage Research Projects | University of California, Los Angeles | Hematopoietic Stem Cell Gene Therapy for X-linked Agammaglobulinemia |
$219,230 |
| Therapeutic Translational Research Projects | University of California, Los Angeles | Autologous MPO Knock-Out Hematopoietic Stem and Progenitor Cells for Pulmonary Arterial Hypertension |
$4,751,297 |
| Conference II | University of California, Los Angeles | Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
| Clinical Trial Stage Projects | University of California, Los Angeles | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Clinical Trial Stage Projects | University of California, Los Angeles | A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
| Disease Team Therapy Development III | University of California, Los Angeles | Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$13,145,465 |
| Early Translational IV | University of California, Los Angeles | Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells |
$1,651,884 |
| Disease Team Research I | University of California, Los Angeles | Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
